Health Canada Approves New Heart Treatment Technology
Health Canada has officially approved the Affera mapping and ablation system, a new medical technology developed by the company Medtronic. This system is designed to help doctors treat patients who suffer from heart rhythm disorders, also known as arrhythmias.
Heart rhythm disorders occur when the heart beats too fast, too slow, or with an irregular pattern. The Affera system provides physicians with an all-in-one platform to map the heart’s electrical activity and perform ablation, a procedure that uses heat or cold to destroy small areas of heart tissue that cause irregular beats.
By combining these two functions into one platform, the technology aims to make heart procedures more efficient for medical teams. Improved efficiency can lead to shorter surgery times and better outcomes for patients undergoing cardiac care across Canada.
Medtronic stated that this approval is an important step in expanding treatment options for Canadians with heart conditions. The company plans to begin introducing the system to hospitals and clinics in the coming months.
This development is part of a broader trend of integrating advanced digital tools into Canadian healthcare. As these technologies become available, they are expected to help medical professionals manage complex heart conditions more effectively.